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abstract: Pregnancy is dependent upon the endometrium acquiring a receptive phenotype that facilitates apposition, adhesion and
invasion of a developmentally competent embryo. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry of mid-
secretory endometrial biopsies revealed a 28 kDa protein peak that discriminated highly between samples obtained from women with recur-
rent implantation failure and fertile controls. Subsequent tandem mass spectroscopy unambiguously identified this peak as apolipoprotein A-I
(apoA-I), a potent anti-inflammatory molecule. Total endometrial apoA-I levels were, however, comparable between the study and control
group. Moreover, endometrial apoA-I mRNA expression was not cycle-dependent although there was partial loss of apoA-I immunoreac-
tivity in luminal and glandular epithelium in mid-secretory compared with proliferative endometrial samples. Because of its putative anti-
implantation properties, we examined whether endometrial apoA-I expression is regulated by embryonic signals. Human chorionic gonado-
trophin (hCG) strongly inhibited apoA-I expression in differentiating explant cultures but not when established from eutopic endometrium
from patients with endometriosis. Pelvic endometriosis was associated with elevated apoA-I mRNA levels, increased secretion by differen-
tiating eutopic endometrial explant cultures and lack of hCG-dependent down-regulation. To corroborate these observations, we examined
endometrial apoA-I expression and its regulation by hCG in a non-human primate model of endometriosis. As in humans, hCG strongly
inhibited endometrial apoA-I mRNA expression in disease-free baboons, but this response was entirely lost upon induction of pelvic endo-
metriosis. Together, these observations indicate that perturbations in endometrial apoA-I expression, modification or regulation by paracrine
embryonic signals play a major role in implantation failure and infertility.
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Introduction
In humans and other mammals with invasive placentae, implantation
involves apposition of the blastocyst to the luminal epithelium of the
endometrium, followed by adhesive contact and then invasion of
maternal tissues (Fazleabas and Kim, 2003; Genbacev et al., 2003;
Dey et al., 2004). The apical membranes of epithelial cells are not nor-
mally adhesive, and the endometrial luminal epithelium must transiently
acquire a receptive phenotype to allow attachment of the blastocyst
(Denker, 1993; Rahnama et al., 2009). Interestingly, endometrial recep-
tivity is both species-specific and selective for embryonic trophoblast
(Hohn et al., 2003). In humans, the period of endometrial receptivity,
often referred to as the ‘implantation window’, starts 6 days (d) after
ovulation and is thought to last between 2 and 4 d (Wilcox et al.,
1999; Quinn and Casper, 2009). A shortened or absent receptive
phase is widely believed to be a major cause of conception delay,
which affects 10% of couples during the reproductive years, and to
contribute to the relatively low success rates of assisted reproductive
technologies, such as IVF (Boivin et al., 2007; Diedrich et al., 2007;
Feroze-Zaidi et al., 2007). Conversely, implantation beyond the
normal period of endometrial receptivity is strongly associated with
early pregnancy loss (Wilcox et al., 1999), which is probably accounted
for by the nidation of developmentally compromised embryos.
Endometrial receptivity is dependent upon regulation of evolutiona-
rily conserved gene networks that control the expression of key tran-
scription factors (e.g. HOXA10, STAT3, p53) (Catalano et al., 2005;
Nakamura et al., 2006; Hu et al., 2007; Vitiello et al., 2007; Lynch
et al., 2008), growth factors and cytokines [e.g. HB-EGF,
leukaemia-inhibiting factor (LIF), prokineticin 1] (Stewart et al., 1992;
Evans et al., 2009; Lim and Dey, 2009) and cell adhesion molecules
and their ligands (e.g. avb3 integrin, trophinin, L-selectin ligand)
(Aoki and Fukuda, 2000; Genbacev et al., 2003; Donaghay and
Lessey, 2007), all of which are essential for coordinated cross-talk
with the implanting embryo. Microarray analyses have been exten-
sively used to identify the gene networks that underpin either the
receptive and unreceptive states of the endometrium (Carson et al.,
2002; Kao et al., 2002, 2003; Mirkin et al., 2005; Talbi et al., 2006;
Feroze-Zaidi et al., 2007). Although each study yielded numerous can-
didate genes, the number of common ‘endometrial receptivity’ genes
is relatively small (Horcajadas et al., 2007), probably due to differences
in experimental approach, timing of endometrial sampling and array
platforms used. Nevertheless, impaired expression of endometrial
receptivity genes is increasingly linked to common reproductive dis-
orders. A case in point is endometriosis, a prevalent disorder that
affects 5–10% of women and a major cause of subfertility (Bulun,
2009). This disease is not only characterized by the presence of
pelvic endometrial implants but also, especially during the early- and
mid-secretory phase of the cycle, by gross perturbations in gene
expression in the eutopic endometrium (Burney et al., 2007), including
key regulators of implantation such as HOXA10 and avb3 integrin
(Taylor et al., 1999; Donaghay and Lessey, 2007).
The extent to which endometrial receptivity is perturbed in
subfertile patients without overt pathology is as yet not well defined
(Dimitriadis et al., 2007). On the basis of microarray analysis, we
reported that unexplained infertility is associated with enhanced
expression and activation of serum and glucocorticoid regulated
kinase 1, a serine/threonine kinase essential for uterine fluid handling,
during the mid-secretory phase of the cycle (Feroze-Zaidi et al., 2007).
More recently, various techniques have been employed to survey the
endometrial proteome in proliferative and secretory samples
(DeSouza et al., 2005) and to identify key proteins that may discrimi-
nate between the pre-receptive and receptive phase of the cycle
(Dominguez et al., 2009). In the present study, we also used a proteo-
mic approach to screen for abnormalities during the putative window
of endometrial receptivity in patients with unexplained recurrent
implantation failure (RIF), defined as a failure to achieve a positive
pregnancy test after 3 or more consecutive IVF treatment cycles
with transfer of good-quality embryos. Our data suggest that RIF is
associated with a distinct endometrial protein fingerprint. Moreover,
we identified apolipoprotein A-I (apoA-I) as an endometrial factor
whose expression and regulation in response to embryonic signals
are dysregulated in endometriosis.
Methods and Materials
Patient selection and sample collection
The Local Research and Ethics Committees of Hammersmith and
Addenbrooke’s Hospitals NHS Trusts, UK, approved the study.
Written informed consent was obtained from 15 women with
proven fertility (control group) and from 10 patients with three or
more consecutive IVF treatment failures that could not be attributed
to poor embryo quality (study group). All patients had regular cycles
and their daily urinary luteinizing hormone (LH) levels were monitored
using an ovulation prediction kit (Assure Ovulation Predictor, San
Diego, CA, USA). Endometrial biopsies, timed between 5 and 10 d
following the pre-ovulatory LH surge (LHþ5 to LHþ10), were
taken using a pipelle catheter. The demographic details of the study
and control groups used in the proteomic analysis are summarized
in Table I. Each biopsy was divided and one portion snap-frozen in
liquid nitrogen and stored at 2808C. The other portion was fixed
in formalin for histological dating using standard criteria. A venopunc-
ture was also performed and progesterone levels measured to ensure
that ovulation had occurred. For validation studies, additional endo-
metrial samples at the time of laparoscopy for pelvic pain, infertility
or tubal sterilization were obtained. Eutopic endometrial samples
from women without overt pelvic pathology and patients with histo-
logically confirmed endometriosis were used for primary and explant
cultures, and the demographic details of these patients are summar-
ized in Table II.
........................................................................................
Table I Patient characteristics and timing of
endometrial sampling.
Fertile (n 5 15) RIF (n 5 10)
Age (years) 34.33+5.21 36+5.03
Parity 2.07+1.33 0
Cycle length (days) 29.07+1.44 30+2.21
Progesterone level (nmol/l) 40.44+19.01 37.42+21.04
Days from LH peak 8.07+0.80 8.5+0.97
Values represent mean+ SD.
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Proteomic analysis
Endometrial protein profiles were determined by surface-enhanced
laser desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF-MS), using a strong anion-exchange (Q10) and a weak
cation-exchange (CM10) ProteinChip Arrays (Ciphergen Biosystems,
CA, USA). Prior to sample loading, Q10 and CM10 arrays were equili-
brated with 75 ml of binding/wash buffer (50 mM TRIS, 0.1% v/v Triton
X-100 at pH 5.0, 7.5 or 9.5 for Q10; 50 mM ammonium acetate, 0.01%
v/v Triton X-100 at pH 4.0, 6.0 or 7.5 for CM10). Tissue samples were
lysed in buffer containing dithiothreitol 1% w/v, urea 9.5 M, 2% CHAPS,
centrifuged at 13 000 r.p.m. (16.4g) for 1 h at 158C, and protein concen-
tration in the supernatant was determined by Bradford analysis. Samples
were adjusted to 60 mg protein in 100 ml total volume, and 50 ml was
added to each spot in duplicate. Following 30-min incubation with agita-
tion, the spots were washed first three times with 75 ml of binding/wash
buffer and then briefly with water and air-dried. Saturated sinapinic acid
(SPA) ora-cyano-4-hydroxycinnamic acid (CHCA) was applied and the
dried ProteinChip Arrays transferred into the ProteinChip Biomarker
System (Ciphergen Biosystems) in a randomized fashion to remove
handling bias. Following optimization of the laser settings, data were col-
lected from spots 20 to 80, delta 5 with 16 shots collected per position,
preceded by two warming shots at the appropriate laser setting, the data
from which were discarded. Using Biomarker Wizard software 3.0
(Ciphergen Biosystems), the spectra were normalized to total ion
current over a mass range appropriate to the matrix used (2–10 kDa
for CHCA and 10–50 kDa for SPA). The settings used to autodetect
peaks to cluster in the first pass were a signal-to-noise ratio of 5, second-
pass signal-to-noise ratio of 2 and a mass tolerance of 0.3%. All peaks
detected were required to be present in at least 5% of the spectra to
avoid the inclusion of peaks with poor discriminatory power. The
number of peaks, dependent on ProteinChip and wash condition,
varied 17–78.
We set out to characterize the 11 987 and 28 063 Da protein
peaks, as we reasoned they could serve as the most informative bio-
marker of unreceptive endometrium. Briefly, protein lysates were sub-
jected to reverse-phase fractionation, resolved on sodium dodecyl
sulphate (SDS)–poly acrylamide gel (PAGE) followed by in-gel
trypsin digestion of the proteins of interest and SELDI-TOF-MS analy-
sis. However, the 11 987 protein peak was resistant in-gel trypsin
digestion, thereby precluding further analysis. The analysis of the
28 063 Da protein yielded 23 peptide mass fingerprints, which
were submitted to ProFound (http://prowl.rockefeller.edu/
prowl-cgi/profound.exe), taking in account potential protein modifi-
cations such as methionine oxidation. The protein of interest was
identified as apoA-I precursor (Z ¼ 2.43, 47% coverage), and this
was confirmed by Q-Star MS/MS analysis (data not shown).
Primary human endometrial stromal cell
cultures and endometrial explants
Human endometrial stromal cells (HESCs) were separated from epi-
thelial cells, passed into culture and decidualized in DMEM/F-12 con-
taining 2% dextran-coated carbon-stripped fetal bovine serum with
0.5 mM 8-br-cAMP (Sigma) and 1026 M medroxy-progesterone acte-
tate (MPA) (Sigma) for 24 or 72 h (Brosens et al., 1999), in the pres-
ence or absence recombinant human chorionic gonadotrophin (hCG;
Sigma). All experiments were carried out before the third cell passage
in three or more biological replicates. Explants cultures were also pre-
pared. Briefly, 24 endometrial fragments, measuring approximately 2–
3 mm2 each, were placed in Millicell-CM culture inserts in six-well
plates containing DMEM/F-12 medium supplemented L-glutamine
(1%) and penicillin and streptomycin (1%). The explants were cultured
for 24 h in the presence of 0.5 mM 8-br-cAMP (Sigma) and 1026 M
MPA with or without hCG.
Animals studies
Cycling female baboons (Papio anubis), ranging in age from 7 to 12
years and weighing between 12 and 18 kg, were housed in individual
cages in the Biological Research Laboratories of the University of Illi-
nois. All animal procedures were approved by the Animal Care Com-
mittee of the University of Illinois at Chicago. Endometriosis was
experimentally induced in five female baboons with regular menstrual
cycles by intraperitoneal inoculation of menstrual endometrium on
two consecutive menstrual cycles, and endometrial tissues were
obtained between 3 and 15 months post-inoculation following treat-
ment with CG. Details of the inoculation procedure have been
described previously (Fazleabas et al., 2002, 2003). Uterine tissue
was obtained from six control baboons and five animals induced
with disease by endometriectomy or hysterectomy, on d 10 post-
ovulation (PO). Ovulation was detected in cycling female baboons
by measuring peripheral serum levels of estradiol, beginning 7 d
after the first day of menses. The day of the estradiol surge was desig-
nated as d 2 1, with d 0 as the day of the ovulatory LH surge and d 1
as the day of ovulation. On d 5 PO, an oviductal cannula was attached
to an Alzet osmotic minipump, and recombinant hCG was infused at
the rate 1.25 IU/h for 5 d, as described previously (Fazleabas et al.,
1999). For the enzyme-linked immunosorbent assay (ELISA), serum
was collected from four control and four baboons with endometriosis
during the later stages of the disease.
Immunohistochemistry, western blot
and ELISA
Formalin-fixed, paraffin-embedded samples were stained for apoA-I
expression. Briefly, after mounting, the samples were de-paraffinized
and rehydrated in graded concentrations of ethanol, and endogenous
peroxidase activity was blocked by immersion of the slides for 30 min
........................................................................................






Age (mean+ SD) 33.3+4.6 years 34.9+5.1 years*
Parity 0.5+1 0.8+0.9*
Proliferative samples 11 11
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in a freshly prepared solution of 2 ml of 30% hydrogen peroxide
diluted in 200 ml of methanol. The slides were then washed in PBS,
pre-incubated in 1.5% non-immune murine serum in PBS for 30 min
at RT and incubated overnight at 48C with a mouse monoclonal
apoA-I antibody (1:50 dilution; Calbiochem, Nottingham, UK) and
the staining visualized using biotinylated goat anti-mouse IgG (Vector
Laboratories, Peterborough, UK). Liver tissue sections were included
as positive control, and the primary antibody was omitted as a nega-
tive control. The tissue sections of proliferative and secretory endo-
metrium have been described elsewhere (Goto et al., 2008).
Additional tissue sections of mid-secretory endometrium from
patients with and without endometriosis, proven by laparoscopy,
were provided by S.L.Y. and B.A.L., respectively.
Total protein lysates from snap-frozen samples and primary cultures
were subjected to western blot analysis as described previously
(Pohnke et al., 2004). The mouse monoclonal antibodies against
apoA-I and b-actin (Abcam, Cambridge, UK) were diluted at 1:5000
and 1:100 000, respectively. apoA-I levels in the supernatant of endo-
metrial explants maintained in serum-free cultures were determined
using ELISA (AlerCHEK, Portland, ME, USA), according to the manu-
facturer’s instructions, and the data were normalized to the weight of
the explants in each culture. Serum apoA-I and high-density lipopro-
tein (HDL) levels were measured by the Clinical Pathology Laboratory
at Hammersmith Hospital, London, UK.
Real-time quantitative PCR
Real-time quantitative PCR (RTQ-PCR) analysis was performed as
described previously (Feroze-Zaidi et al., 2007). All measurements
were performed in triplicate. The following gene-specific primer
pairs, designed using the ABI Primer Express software, were used:
apoA-I-sense (50-GGC AGA GAC TAT GTG TCC CAG TT-30) and
apoA-I-antisense (50-GTC CCA GTT GTC AAG GAG CTTT-30);
L19-sense (50-GCG GAA GGG TAC AGC CAA T-30) and
L19-antisense (50-GCA GCC GGC GCA AA-30). RTQ-PCR analysis
for b-actin has been described previously (Cornet et al., 2005).
Statistical analysis
Differences in protein peaks were analysed with Ciphergen Express
Software, which uses the Mann–Whitney non-parametric test to cal-
culate statistically significant differences across the groups (P , 0.05).
In addition, the two-tailed Student’s t-test (demographic details of
patients groups) and Wilcoxon signed-rank matched-pairs test (endo-
metriosis data) were used, as appropriate, to test for significance
between groups.
Results
Proteomic profiling of mid-secretory
endometrium in RIF and controls
To provide insights into pathological mechanisms that interfere with
embryo implantation, we used SELDI-TOF-MS to survey the endo-
metrial proteome of 15 women with proven fertility (control group)
and 10 patients with three or more consecutive IVF treatment failures
that could not be attributed to poor embryo quality (RIF group). For
practical reasons, samples were obtained during a 6-day period in the
menstrual cycle (LHþ5 to þ10) that spans the putative window of
implantation. The relative intensities of four protein peaks, all detected
on the strong anionic exchange Q10 array (pH 5.0), were significantly
different between the study and control groups. Figure 1 shows the
normalized spectra of the single most discriminatory peak, corre-
sponding to a protein of 28 063 Da, whereas Fig. 2 represents
scatter plots of all four protein peaks. The relative intensities of two
peaks, corresponding to proteins of 11 987 and 28 063 Da,
were 2.7- and 4.2-fold higher in the study group compared with the
control group, respectively (Fig. 2A and B). Conversely, the average
intensities of the 15 867 and 16 075 Da peaks were significantly
lower in samples from patients with multiple IVF treatment failure
(Fig. 2C and D). The data show that protein fingerprints exist,
capable of discriminating between RIF and control endometrium.
Identification of apoA-I in receptive
and unreceptive endometrium
As shown in Fig. 2B, the normalized intensities of the 28 kDa protein
peak clustered together in all 15 control samples, whereas they were
considerably higher in 7 out of 10 RIF samples. Therefore, we set out
to characterize this 28 kDa protein peak, as we reasoned it could
serve as the most informative biomarker of unreceptive endometrium.
Briefly, protein lysates were subjected to reverse-phase fractionation,
resolved by SDS–PAGE followed by in-gel trypsin digestion of the
28 kDa band and SELDI-TOF-MS analysis (data not shown). The
resulting peptide mass fingerprints were submitted to ProFound
(http://prowl.rockefeller.edu/prowl-cgi/profound.exe), taking in
account potential protein modifications, such as methionine oxi-
dation. The protein of interest was identified as apoA-I precursor,
and this was unambiguously confirmed by Q-Star MS/MS analysis
(data not shown). Notably, the apoA-I precursor encodes for a
protein with a theoretical mass of 30 276 Da but, after cleavage of
the peptide signal and pro-peptide, the molecular weight of mature
apoA-I is 28 078 Da.
To validate these findings, we examined apoA-I expression levels by
western blot analysis in 10 receptive and 9 unreceptive endometrial
samples also used in the SELDI-TOF-MS screen. Although the abun-
dance of apoA-I varied between samples, there was no apparent
increase in endometrial biopsies obtained from RIF patients (Fig. 3A)
or an obvious correlation with the SELDI-TOF-MS spectra (Fig. 1).
The abundance of apoA-I transcripts in the endometrium was several
magnitudes lower when compared with the liver (data not shown),
raising the possibility that endometrial protein levels may, at least in
part, reflect circulating levels. Although there was a trend towards
higher apoA-I and HDL plasma levels in patients with RIF compared
with fertile controls, this was not statistically significant (Fig. 3B). Thus,
endometrial and circulating apoA-I levels were comparable between
control and study patients, suggesting that the more efficient capture
of apoA-I from RIF samples on the strong anionic exchange Q10 array
may have been due to protein modifications, such as oxidation or sialyla-
tion, that enhance the negative charge of apoA-I.
Expression and regulation of endometrial
apoA-I is impaired in endometriosis
Although western blot analysis did not support a clear association of
RIF with enhanced apoA-I levels, we set out to further characterize
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the expression and regulation of this lipoprotein in the endometrium
for two reasons. First, apoA-I has potent anti-inflammatory properties
(Hyka et al., 2001; Rohrer et al., 2006; Van Lenten et al., 2009), raising
the possibility that the expression of this lipoprotein in the endome-
trium may be restricted to the peri-implantation window. Second,
we recently identified apoA-I in the baboon uterus as a gene
repressed in response to hCG infusion (Sherwin et al., 2007). We
first examined whether apoA-I expression in the human endometrium
is subject to cycle-dependent regulation. RTQ-PCR analysis revealed
no significant differences in apoA-I mRNA levels between proliferative,
secretory or menstrual endometrial samples (Fig. 4A; P . 0.05). Simi-
larly, western blot analysis showed apoA-I expression throughout the
cycle, although levels appeared more variable in secretory compared
with proliferative endometrium (Fig. 4B). Immunohistochemistry of
paraffin-embedded samples showed strong apoA-I staining in prolifera-
tive endometrium, which was equally prominent in the epithelial and
stromal compartments (Fig. 4C). By the mid-secretory phase of the
cycle, however, apoA-I immunoreactivity in the epithelial compart-
ment was decreased and patchy, especially in the luminal epithelium,
whereas staining in the stroma appeared largely unchanged. In view
of the unaltered transcript levels, the lower and patchy immunostain-
ing in epithelial cells suggests that apoA-I is actively secreted during the
luteal phase of the cycle.
Next we examined whether embryonic signals, and more specifically
hCG, antagonize apoA-I expression in the human endometrium, as has
been reported for the baboon (Sherwin et al., 2007). To determine the
Figure 1 Normalized SELDI-TOF-MS of mid-secretory endometrial biopsies from fertile women (A) and RIF patients (B) reveal a discriminatory
28 063 mass-to-charge (m/z) protein peak. Sample numbers are indicated on the right. The X-axis denotes the m/z values, whereas the Y-axis is a
relative intensity scale. The mass spectra were obtained at pH 5.0 on Q10 chips, which capture positively charged proteins due to its negatively
charged surface.
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optimal treatment conditions, the effect of hCG on apoA-I expression
was first studied in undifferentiated primary endometrial stromal cells
(ESCs) or cells differentiated for 24 or 72 h in response to 8-br-cAMP
and MPA, a progestin (Jones et al., 2006). Intriguingly, hCG markedly
reduced apoA-I levels in differentiating (decidualizing) but not in
undifferentiated ESCs (Fig. 5A). Moreover, the effect of hCG on
apoA-I expression in decidualizing cells was time- and dose-dependent
and mimicked at transcript level (data not shown). To examine whether
this hCG response is maintained within the context of a complex tissue,
we established endometrial explant cultures from fresh biopsy samples.
Figure 2 Relative intensities of the four discriminatory protein peaks with m/z values of 11 987 (A), 28 063 (B), 15 867 (C) and 16 075 (D). Open
circles represent the values of individual samples. Horizontal bars denote the median of normalized intensities.
Figure 3 Endometrial apoA-I expression and plasma levels in fertile and infertile patients during the mid-luteal phase of the cycle. (A) Nineteen of
the 25 endometrial samples used for SELDI-TOF-MS were resolved on SDS–PAGE and immunoblotted for apoA-I. Control samples from fertile
patients are indicated as C1-10, whereas biopsies from patients with RIF are denoted RIF1-9. b-Actin served as loading control. (B) Circulating
apoA-I and HDL levels at the time of biopsy were determined in serum samples of fertile women (controls, n ¼ 15) and patients with RIF
(n ¼ 10); P . 0.05.
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On the basis of the findings in primary ESCs, the explants were main-
tained in the presence of 8-br-cAMP and MPA and treated with or
without hCG for 24 h. As shown in Fig. 5B, hCG was effective in
inhibiting apoA-I mRNA and protein levels although, strikingly, not in
explant cultures established from eutopic endometrium of patients
with endometriosis. Moreover, endometrial explants from
Figure 4 apoA-I expression and tissue distribution in proliferative and secretory endometrium. (A) RTQ-PCR analysis of apoA-I mRNA expression
throughout the cycle. The relative expression level of apoA-I transcripts, normalized to b-actin mRNA, was determined in 33 endometrial samples,
spanning the entire menstrual cycle. The results are presented on a logarithmic scale. (B) Western blot analysis of apoA-I expression in proliferative
(P1-5) and secretory (S1-6) endometrial samples. b-Actin served as loading control. (C) apoA-I immunolocalization in proliferative and secretory
endometrium. apoA-I staining, performed on five proliferative endometrial samples (cycle days 8–12), was equally prominent in surface epithelium,
glandular epithelium and the stromal compartment (a, b). In surface epithelium, apoA-I was expressed predominantly at the apical border of the cells
(a). Immunostaining decreased markedly in the glandular but not stromal compartment in mid-secretory endometrium (cycle days 19–24; n ¼ 6),
whereas apoA-I expression in luminal epithelial cells appeared highly variable (c, d).
Endometrial apoA-I in implantation failure and endometriosis 279
Figure 5 Regulation of endometrial apoA-I expression by hCG. (A) Undifferentiated human endometrial stroma cells (ESCs) and cultures decid-
ualized with 8-Br-cAMP and MPA were co-treated with or without hCG for the indicated time-points. Total protein lysates were subjected to western
blot analysis for apoA-I. The membranes were then probed for a-tubulin, a loading control. (B) Endometrial explants established from patients with
and without endometriosis were cultured for 24 h in the presence of 8-Br-cAMP and MPA with or without hCG. Parallel cultures were harvested for
western blot or RTQ-PCR analyses. (C) The supernatant of explant cultures established from eutopic endometrial samples from patients with and
without endometriosis were analysed for apoA-I using ELISA. The levels were normalized to the weight of the explants. *P , 0.01. (D) apoA-I mRNA
levels determined by RTQ-PCR in snap-frozen, luteal-phase, eutopic, endometrial samples from patients with (n ¼ 5) and without pelvic endometrio-
sis (n ¼ 5); *P , 0.01.
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endometriosis patients were characterized by much higher apoA-I
mRNA but lower protein levels, suggesting either a translational block
or active secretion. To differentiate between these possibilities, fresh
explant cultures were established and cultured in serum-free medium
for 24 h. Analysis of the supernatant confirmed that apoA-I is more
readily secreted by endometrial explants from patients with endome-
triosis compared with disease-free controls (Fig. 5C). Moreover,
RTQ-PCR analysis of snap-frozen secretory endometrial samples con-
firmed that pelvic endometriosis is associated with increased expression
of apoA-I mRNA transcripts in vivo (Fig. 5D).
To corroborate these observations, the expression pattern of
apoA-I in mid-secretory endometrial samples (LHþ6 to þ10) from
patients with endometriosis (n ¼ 8) was examined by immunohisto-
chemistry and compared with disease-free controls (n ¼ 8). As exem-
plified in Fig. 6A, apoA-I immunoreactivity in the luminal and glandular
epithelial compartments was invariable patchy in control tissue
sections. In contrast, six out of eight biopsies from endometriosis
patients showed strong staining of the luminal epithelial cells,
whereas the glands often showed little or no apoA-I expression.
Next, we explored whether failure of hCG to antagonize endo-
metrial apoA-I expression was a direct consequence of the presence
of pelvic endometriosis. To this end, we determined endometrial
apoA-I mRNA levels upon hCG infusion in the baboon uterus
before and after the induction of pelvic endometriosis. As shown
in Fig. 6B, endometrial apoA-I transcript levels remained elevated
in response to in vivo uterine hCG infusion in baboons with endome-
triosis, whereas a significant decrease in mRNA expression was
evident in disease-free animals. Interestingly, circulating serum
levels of apoA-I also increased in baboons 3 and 12 months after
induction of pelvic endometriosis (Fig. 6C). The data in Fig. 6B
and C represent sampling of the same animals during the course
of the disease process.
Figure 6 Endometriosis is associated with aberrant endometrial apoA-I expression in human and baboon endometria. (A) apoA-I staining in mid-
secretory endometrium (cycle days 8–12) in disease-free controls (a–c; n ¼ 8) and patients with endometriosis (d–f; n ¼ 8). (B) RTQ-PCR analysis
of endometrial RNA obtained from control animals (n ¼ 4) and baboons with endometriosis (n ¼ 5) following hCG infusion. Different letters above
the error bars indicate that those groups are significantly different from each other at P , 0.05. (C) Sequential serum samples were obtained from
baboons (n ¼ 4) at 3 and 12 months following the induction of endometriosis and circulating apoA-I levels compared with those from control disease-
free baboons (n ¼ 4) at the same point during the menstrual cycle, i.e. between d 9 and 11 PO. Different letters above the error bars indicate that
those groups are significantly different from each other at P , 0.05.
Endometrial apoA-I in implantation failure and endometriosis 281
Discussion
apoA-I is best known as the major protein component of circulating
HDL and the primary acceptor for cholesterol in extra-hepatic
tissues. Yet, proteomic analyses of diverse tissue samples and body
fluids other than serum have identified apoA-I as a protein dysregu-
lated in a variety of diseases, ranging from pre-eclampsia, polycystic
ovary syndrome and rheumatoid arthritis to a host of neurological dis-
orders and cancers (Kozak et al., 2005; Yang et al., 2005; Ai et al.,
2006; Corton et al., 2008; Giusti et al., 2008; Park et al., 2008;
Trocme et al., 2008). The relative abundance of apoA-I captured
on ProteinChip platforms often, but not always, correlates with in
vivo expression levels, which in turn reflect either local synthesis or
extravasation of serum proteins in a diseased tissue (Yang et al.,
2005). Here, we investigated apoA-I as a putative biomarker of non-
receptive endometrium, although its increased capture from RIF
samples on a strong anionic exchange array did not correlate with
either total endometrial levels by western blot or circulating apoA-I
levels. It is conceivable that posttranslational modifications, such as
phosphorylation, oxidation, sialylation and acylation (Hoeg et al.,
1986; Holian et al., 1991; Millar, 2001; von Eckardstein et al.,
2005), sufficiently impact on the isoelectric point of apoA-I to
account for the differences in the SELDI-TOF spectra between
control and RIF samples. The broad base of the 28-kDa apoA-I
peak (Fig. 1) is indeed compatible with the presence of modified
protein species.
Embryo implantation first involves binding of L-selectin expressed by
the trophoblast to oligosaccharide ligands present on the endometrial
surface followed by ligand-dependent interactions with other cell
adhesion molecules, such as integrins and trophinin, that produce
stable adherence of the blastocyst to the luminal epithelium (Fazleabas
and Kim, 2003; Genbacev et al., 2003; Dey et al., 2004; Diedrich et al.,
2007; Donaghay and Lessey, 2007). This mechanism is remarkably
similar to that involved in rolling and subsequent adherence of leuco-
cytes to vascular endothelium. It is well established that the serum
apoA-I/HDL concentrations correlate inversely with the risk of cardi-
ovascular disease and, conversely, that patients with lower levels of
apoA-I are more likely to develop systemic inflammatory response
syndrome after major trauma or surgery (Chenaud et al., 2004).
These protective effects of apoA-I are at least partly due to its
ability to inhibit the synthesis of major inflammatory mediators, such
as tumour necrosis factor and interleukin-1b, and to block
cytokine-induced expression of selectins and other cellular adhesion
molecules on endothelium, thereby diminishing neutrophil adherence
and subsequent tissue injury (Hyka et al., 2001; Chenaud et al., 2004;
Liao et al., 2005; Shi and Wu, 2008; Van Lenten et al., 2009). On the
basis of its role in vascular biology, it is tempting to speculate that
apoA-I may also serve to restrict embryo implantation to a confined
period in the cycle and, conversely, that aberrant endometrial
secretion of this lipoprotein contributes to implantation failure.
Several lines of evidence further support this notion. For example,
female mice that lack the HDL receptor (scavenger receptor class
B, type I) are infertile as a consequence of abnormal lipoprotein
metabolism (Miettinen et al., 2001). Interestingly, fertility in these
animals is restored not only upon administration of the cholesterol-
lowering drug, probucol, but also upon simultaneous silencing of the
Apoa1 gene. It is also striking that the postovulatory progesterone
surge triggers in human endometrium the expression of several
genes involved in lipid metabolism, including lipoproteins apoD,
apoL2 and apoE (Talbi et al., 2006). Although we found no evidence
that endometrial APOA1 expression is regulated by ovarian hormones,
immunohistochemistry was compatible with secretion by differentiat-
ing endometrium during the luteal phase, an observation supported
by the detection of apoA-I in the supernatant of endometrial
explant culture. Finally, APOA1 was recently identified as one of rela-
tively few peri-implantation genes repressed upon hCG infusion of
the baboon uterus (Sherwin et al., 2007).
hCG is one of the earliest and most abundant glycoproteins
secreted by embryonic trophoblast. Besides maintaining progester-
one production by the ovarian corpus luteum during the first trime-
ster of pregnancy, hCG exerts numerous direct effects on
progesterone-primed endometrium that are essential for implan-
tation (Licht et al., 2007). For example, hCG has been shown to
enhance the expression of the pro-implantation cytokines prokeneti-
cin 1 and LIF (Perrier d’Hauterive et al., 2004; Evans et al., 2009), to
promote local angiogenesis (Berndt et al., 2006), to stimulate pro-
liferation of specialized uterine natural killer cells (Kane et al.,
2009) and to inhibit apoptosis in decidualizing ESCs (Jasinska et al.,
2006). The observation that hCG inhibition of endometrial apoA-I
expression is a conserved response in humans and other primates
further underscores the importance of this lipoprotein as an anti-
implantation factor.
Perhaps, the most compelling evidence for a causal role of apoA-I in
implantation failure came from the observation that endometriosis is
associated with elevated apoA-I mRNA levels, aberrant expression
in mid-secretory endometrium, increased secretion by differentiating
eutopic endometrial explant cultures and lack of hCG-dependent inhi-
bition. Endometriosis is foremost a pelvic inflammatory disorder
(Bulun, 2009) and a major cause of infertility. A meta-analysis of preg-
nancies after IVF showed that conception rate in women with endo-
metriosis is approximately half that in patients with tubal-factor
infertility (Barnhart et al., 2002). In addition to its aberrant expression
in eutopic endometrium, characterized by enhanced and decreased
apoA-I immunoreactivity in luminal and glandular epithelial compart-
ments, respectively, apoA-I levels are reportedly also higher in the
peritoneal fluid of patients with endometriosis (Ferrero et al., 2007),
suggesting that enhanced secretion of this anti-inflammatory/anti-
implantation lipoprotein in both eutopic and ectopic endometria is a
hallmark of the disease.
Whether or not pelvic inflammation accounts for abnormal gene
expression in the eutopic endometrium during the peri-implantation
period has been a matter of considerable debate (Giudice and Kao,
2004). Here, we show that surgical induction of endometriosis in
the baboon is sufficient to persistently enhance basal endometrial
apoA-I mRNA expression and to abrogate its inhibition by hCG.
Moreover, increased expression of apoA-I transcripts upon induction
of endometriosis in the baboon coincided with an increase in circulat-
ing apoA-I levels. Interestingly, fasting serum apoA-I but not HDL
levels are also significantly higher in women with endometriosis com-
pared with healthy controls (Crook et al., 1997), which may reflect a
hepatic response to elevated levels of circulating inflammatory
mediators (Akoum et al., 1996; Bedaiwy et al., 2002).
This study has raised a number of important questions. For
example, the mechanism of hCG inhibition of endometrial apoA-I
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expression, and its failure in endometriosis, is unknown and warrants
further investigation. As alluded to, apoA-I is subject to numerous
posttranslational modifications (Hoeg et al., 1986; Holian et al.,
1991; Millar, 2001; von Eckardstein et al., 2005), which may or may
not differ between fertile women and RIF patients. These modifi-
cations require further characterization, as they may profoundly
impact on the anti-inflammatory/anti-implantation properties of
uterine apoA-I (von Eckardstein et al., 2005).
In summary, proteomic analysis of timed endometrial samples from
fertile women and patients with unexplained RIF yielded a distinct pro-
teomic fingerprint that may discriminate between receptive and unrec-
eptive endometrium. Our results complement other recent attempts
at characterizing the receptive endometrial proteome (Dominguez
et al., 2009). Whether or not proteomic fingerprinting can be used
clinically to predict the likelihood of pregnancy after IVF treatment is
under evaluation in a prospective study. We also identified apoA-I
as a putative anti-implantation factor secreted by differentiating endo-
metrium and inhibited by embryonic signals. Finally, we demonstrated
that pelvic endometriosis increases apoA-I expression in secretory
endometrium and perturbs its regulation by hCG, an observation
that provides new insights into the mechanisms of implantation
failure and subfertility associated with this debilitating condition.
Together, the data suggest that dysregulation or altered modification
of apoA-1 may be a point of conversion in various pathologies associ-
ated with infertility, such as endometriosis and RIF.
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